AR038394A2 - Forma de dosificacion oral de liberacion espacialmente retardada - Google Patents
Forma de dosificacion oral de liberacion espacialmente retardadaInfo
- Publication number
- AR038394A2 AR038394A2 ARP030100364A ARP030100364A AR038394A2 AR 038394 A2 AR038394 A2 AR 038394A2 AR P030100364 A ARP030100364 A AR P030100364A AR P030100364 A ARP030100364 A AR P030100364A AR 038394 A2 AR038394 A2 AR 038394A2
- Authority
- AR
- Argentina
- Prior art keywords
- sertraline
- dosage form
- release
- period
- delayed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Gynecology & Obstetrics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Forma de dosificación oral de liberación retardada de sertralina que disminuye el Tmax en relación con el Tmax de las formas de dosificación de comprimidos de sertralina de liberación inmediata conocidos actualmente, que liberan una dosis en forma de píldora grande equivalente. En lo que se refiere a las formas de dosificación de liberación inmediata, esta también disminuye la incidencia y/o gravedad de los efectos gastrointestinales y/o de otros efectos secundarios. Una forma de dosificación temporalmente retardada adecuada para la administración oral a un mamífero, caracterizada porque comprende (1) un núcleo de liberación inmediata que comprende sertralina o una sal farmacéuticamente aceptable de la misma y un vehículo farmacéuticamente aceptable y (2) un recubrimiento que rodea dicho núcleo, no liberando sustancialmente dicha forma de dosificación, cuando se ensaya en disolución in vitro en un aparato N° 2 de la USP que contiene 900 ml de tampón ácido acético/acetato, pH 4,0, que es NaCl 0,075M, sertralina durante un primer período de aproximadamente 10 minutos, no liberando más del 10 % de la sertralina incorporada en la misma durante un segundo período que dura hasta 2 horas después de dicho período, y efectuando a continuación la liberación inmediata de la sertralina restante incorporada en la misma después de dicho segundo período
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5149997P | 1997-07-01 | 1997-07-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038394A2 true AR038394A2 (es) | 2005-01-12 |
Family
ID=21971681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100364A AR038394A2 (es) | 1997-07-01 | 2003-02-05 | Forma de dosificacion oral de liberacion espacialmente retardada |
Country Status (40)
| Country | Link |
|---|---|
| EP (1) | EP1007024B1 (es) |
| JP (1) | JP3786715B2 (es) |
| KR (1) | KR100369698B1 (es) |
| CN (4) | CN1475209A (es) |
| AP (1) | AP1199A (es) |
| AR (1) | AR038394A2 (es) |
| AT (1) | ATE245415T1 (es) |
| AU (1) | AU727152B2 (es) |
| BG (1) | BG64742B1 (es) |
| BR (1) | BR9809895A (es) |
| CA (1) | CA2290969C (es) |
| DE (1) | DE69816624T2 (es) |
| DK (1) | DK1007024T3 (es) |
| DZ (1) | DZ2547A1 (es) |
| EA (1) | EA001906B1 (es) |
| ES (1) | ES2202858T3 (es) |
| GT (1) | GT199800091A (es) |
| HN (1) | HN1998000099A (es) |
| HR (1) | HRP980376B1 (es) |
| HU (1) | HUP0301787A3 (es) |
| ID (1) | ID23187A (es) |
| IL (2) | IL152304A0 (es) |
| IS (1) | IS5267A (es) |
| MA (1) | MA24585A1 (es) |
| NO (1) | NO996519L (es) |
| NZ (1) | NZ501249A (es) |
| OA (1) | OA11247A (es) |
| PA (1) | PA8454201A1 (es) |
| PE (1) | PE84399A1 (es) |
| PL (1) | PL337799A1 (es) |
| PT (1) | PT1007024E (es) |
| SI (1) | SI1007024T1 (es) |
| SK (1) | SK173299A3 (es) |
| TN (1) | TNSN98122A1 (es) |
| TR (1) | TR199903295T2 (es) |
| TW (1) | TW575437B (es) |
| UA (1) | UA63953C2 (es) |
| UY (1) | UY25068A1 (es) |
| WO (1) | WO1999001122A1 (es) |
| ZA (1) | ZA985710B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000025752A1 (en) | 1998-11-02 | 2000-05-11 | Church, Marla, J. | Multiparticulate modified release composition |
| IE990406A1 (en) | 1999-05-20 | 2000-12-27 | Elan Corp Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations. |
| CA2374039C (en) * | 1999-05-20 | 2011-01-11 | Elan Corporation Plc | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations |
| DK1225881T3 (da) | 1999-09-03 | 2006-06-12 | Apbi Holdings Llc | Anvendelsen af dapoxetin, en hurtigt-virkende selektiv serotonin genoptagelseshæmmer, til behandling af seksuel dysfunktion |
| ES2168043B1 (es) * | 1999-09-13 | 2003-04-01 | Esteve Labor Dr | Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido. |
| IL150850A0 (en) * | 2000-02-10 | 2003-02-12 | Bpsi Holdings Inc | Enteric coating compositions containing acrylic resin |
| JP2004507502A (ja) | 2000-08-30 | 2004-03-11 | ファイザー・プロダクツ・インク | 成長ホルモン分泌促進物質のための徐放性製剤 |
| US6482440B2 (en) * | 2000-09-21 | 2002-11-19 | Phase 2 Discovery, Inc. | Long acting antidepressant microparticles |
| PT1377276E (pt) * | 2001-04-10 | 2011-12-30 | Sun Pharma Advanced Res Co Ltd | Composição de libertação temporizada por pulso |
| CA2457385A1 (en) * | 2001-08-06 | 2003-02-20 | Dr. Reddy's Laboratories Ltd. | Improved enteric formulation of fluoxetin |
| GB0607534D0 (en) * | 2006-04-13 | 2006-05-24 | Univ London Pharmacy | Colonic drug delivery formulation |
| EP2586429A1 (en) * | 2011-10-26 | 2013-05-01 | Freund Pharmatec Ltd. | Multi-unit drug delivery device for pulsatile or sustained release |
| CN108014087A (zh) * | 2017-12-27 | 2018-05-11 | 江苏联环药业股份有限公司 | 一种盐酸舍曲林胶囊的制备方法 |
| CN109432038A (zh) * | 2018-12-28 | 2019-03-08 | 乐普制药科技有限公司 | 一种含有盐酸舍曲林的肠溶片剂及其制备方法 |
| CN114129540B (zh) * | 2021-11-19 | 2022-07-05 | 浙江维康药业股份有限公司 | 一种肝苏胶囊及其制作方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK150008C (da) * | 1981-11-20 | 1987-05-25 | Benzon As Alfred | Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat |
| US4803076A (en) * | 1986-09-04 | 1989-02-07 | Pfizer Inc. | Controlled release device for an active substance |
| EP0357364B1 (en) * | 1988-08-30 | 1993-07-28 | E.I. Du Pont De Nemours And Company | A process for flash-spinning dry polymeric plexifilamentary film-fibril strands |
| IL91398A (en) * | 1988-08-30 | 1994-05-30 | Pfizer | Pharmaceutical delivery device comprising active substance surrounded by asymmetric membrane |
| US4983401A (en) * | 1989-05-22 | 1991-01-08 | Kinaform Technology, Inc. | Sustained release pharmaceutical preparations having pH controlled membrane coatings |
-
1998
- 1998-06-16 HU HU0301787A patent/HUP0301787A3/hu unknown
- 1998-06-16 BR BR9809895-0A patent/BR9809895A/pt not_active Application Discontinuation
- 1998-06-16 AU AU75451/98A patent/AU727152B2/en not_active Ceased
- 1998-06-16 PL PL98337799A patent/PL337799A1/xx unknown
- 1998-06-16 CN CNA031489737A patent/CN1475209A/zh active Pending
- 1998-06-16 NZ NZ501249A patent/NZ501249A/en unknown
- 1998-06-16 EA EA199900965A patent/EA001906B1/ru unknown
- 1998-06-16 CN CNA200310118311XA patent/CN1494899A/zh active Pending
- 1998-06-16 CA CA002290969A patent/CA2290969C/en not_active Expired - Fee Related
- 1998-06-16 SI SI9830494T patent/SI1007024T1/xx unknown
- 1998-06-16 DK DK98923022T patent/DK1007024T3/da active
- 1998-06-16 IL IL15230498A patent/IL152304A0/xx unknown
- 1998-06-16 ES ES98923022T patent/ES2202858T3/es not_active Expired - Lifetime
- 1998-06-16 ID IDW991698A patent/ID23187A/id unknown
- 1998-06-16 EP EP98923022A patent/EP1007024B1/en not_active Expired - Lifetime
- 1998-06-16 IL IL13308198A patent/IL133081A/xx not_active IP Right Cessation
- 1998-06-16 UA UA99116392A patent/UA63953C2/uk unknown
- 1998-06-16 KR KR10-1999-7011529A patent/KR100369698B1/ko not_active Expired - Fee Related
- 1998-06-16 CN CNA031489729A patent/CN1475208A/zh active Pending
- 1998-06-16 TR TR1999/03295T patent/TR199903295T2/xx unknown
- 1998-06-16 CN CNB988064294A patent/CN1151783C/zh not_active Expired - Fee Related
- 1998-06-16 WO PCT/IB1998/000937 patent/WO1999001122A1/en not_active Ceased
- 1998-06-16 PT PT98923022T patent/PT1007024E/pt unknown
- 1998-06-16 JP JP50677799A patent/JP3786715B2/ja not_active Expired - Fee Related
- 1998-06-16 DE DE69816624T patent/DE69816624T2/de not_active Expired - Fee Related
- 1998-06-16 SK SK1732-99A patent/SK173299A3/sk unknown
- 1998-06-16 AT AT98923022T patent/ATE245415T1/de not_active IP Right Cessation
- 1998-06-25 PA PA19988454201A patent/PA8454201A1/es unknown
- 1998-06-25 TW TW087110269A patent/TW575437B/zh active
- 1998-06-25 AP APAP/P/1998/001278A patent/AP1199A/en active
- 1998-06-26 PE PE1998000577A patent/PE84399A1/es not_active Application Discontinuation
- 1998-06-29 UY UY25068A patent/UY25068A1/es not_active IP Right Cessation
- 1998-06-29 GT GT199800091A patent/GT199800091A/es unknown
- 1998-06-30 TN TNTNSN98122A patent/TNSN98122A1/fr unknown
- 1998-06-30 HN HN1998000099A patent/HN1998000099A/es unknown
- 1998-06-30 DZ DZ980157A patent/DZ2547A1/xx active
- 1998-06-30 MA MA25144A patent/MA24585A1/fr unknown
- 1998-06-30 ZA ZA9805710A patent/ZA985710B/xx unknown
- 1998-07-01 HR HR980376A patent/HRP980376B1/xx not_active IP Right Cessation
-
1999
- 1999-11-23 BG BG103916A patent/BG64742B1/bg unknown
- 1999-11-23 IS IS5267A patent/IS5267A/is unknown
- 1999-12-23 OA OA9900307A patent/OA11247A/en unknown
- 1999-12-28 NO NO996519A patent/NO996519L/no not_active Application Discontinuation
-
2003
- 2003-02-05 AR ARP030100364A patent/AR038394A2/es active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038394A2 (es) | Forma de dosificacion oral de liberacion espacialmente retardada | |
| AR036768A1 (es) | Formas de administracion de propiverina o sus sales farmaceuticamente aceptables con liberacion prolongada de la sustancia activa | |
| PE71699A1 (es) | Composicion farmaceutica de descarboetoxiloratadina sin lactosa, no higroscopica y anhidra | |
| AR015919A1 (es) | Formas de dosificacion de liberacion sostenida de sertralina, sales de sertralina ,composicion farmaceutica, procedimiento depreparacion y su uso en terapias. | |
| ES2733044T1 (es) | Composición farmacéutica que contiene oxicodona y naloxona | |
| CA2136411A1 (en) | Immediate Release Tablet Cores of Insoluble Drugs Having Sustained Release Coating | |
| ATE213629T1 (de) | Milnacipranhaltige darreichungsform mit verzögerter wirkstoffabgabe | |
| AR037255A1 (es) | Composiciones farmaceuticas que contienen oxibutinina | |
| ATE30380T1 (de) | Pharmazeutische formulierungen mit mehrfachen einheiten. | |
| ES2530719T3 (es) | Formulaciones de oxicodona para ser administradas una vez al día | |
| CA2126611A1 (en) | Opiod Formulations Having Extended Controlled Release | |
| AR013520A1 (es) | Metodo de preparacion de un dispositivo de administracion transdermal, dispositivo de administracion transdermal y utilizacion de un esteroide comoaditivo en un dispositivo de administracion transdermal | |
| JPS63139128A (ja) | Ｌ―ドーパ含有組成物 | |
| ES2055177T3 (es) | Composicion de gemfibrozil con liberacion modificada. | |
| ATE43497T1 (de) | Pharmazeutische formulierung mit gesteuerter absorption. | |
| AR020803A1 (es) | Una composicion que comprende fexofenadina o una sal farmaceuticamente aceptable de la misma y el uso de la misma para la manufactura de unmedicamento | |
| ES2194832T3 (es) | Formulaciones de ditiazem con absorcion controlada. | |
| CN101193638A (zh) | 用于良性前列腺肥大疗法的组合 | |
| US20240216299A1 (en) | Transmucosal therapeutic system containing agomelatine | |
| ES3021732T3 (en) | Soluble rear layer for otf | |
| JP2005528430A5 (es) | ||
| ES2029228T3 (es) | Procedimiento para la produccion de un preparado retardado de ibuprofeno. | |
| LT3119B (en) | Pharmaceutical composition and process for the preparation thereof | |
| JP7705862B2 (ja) | アゴメラチンを含有する経粘膜治療システム | |
| WO1999059557A1 (fr) | Forme pharmaceutique multiparticulaire a liberation programmee et pulsee et son procede de preparation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |